Ειδήσεις: IMMUNOTHERAPY | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 15:37 investing.com

ImmunityBio stock tumbles after FDA warning on misleading ads

ImmunityBio FDA warning misleading ads stock drop cancer immunotherapy regulatory compliance

19/03 07:34 defenseworld.net

Innate Pharma (IPHYF) Expected to Announce Quarterly Earnings on Thursday

Innate Pharma earnings biotech oncology immunotherapy stock

18/03 08:47 defenseworld.net

Hemispherx BioPharma (NYSEAMERICAN:HEB) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

Hemispherx BioPharma stock moving average immunotherapy viral infections

17/03 02:18 sciencedaily.com

Scientists inject one tumor and watch cancer vanish across the body

CD40 agonist tumor injection systemic regression immunotherapy clinical trial metastatic cancer

15/03 23:56 yahoo.com

This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss

Merck KEYTRUDA exclusivity loss immunotherapy combination therapy pipeline

15/03 20:45 yahoo.com

Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies

Amgen anti‑OX40 clinical trials immunotherapy oncology drug development

15/03 20:45 yahoo.com

Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies

Amgen anti‑OX40 clinical trials immunotherapy oncology drug development

Loading...